🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 1 día
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 08/10/2007 | 37,36 | 37,36 | 35,97 | 36,59 | -2,06% | 3,72% | 1.286.700 |
| 05/10/2007 | 37,56 | 37,56 | 36,58 | 37,36 | -0,13% | 2,61% | 1.497.700 |
| 04/10/2007 | 37,23 | 37,91 | 37,05 | 37,41 | +0,38% | 2,31% | 1.026.500 |
| 03/10/2007 | 37,47 | 37,98 | 37,13 | 37,27 | -0,51% | 2,27% | 1.143.200 |
| 02/10/2007 | 39,03 | 39,03 | 37,22 | 37,46 | -3,90% | 4,64% | 1.745.700 |
| 01/10/2007 | 38,46 | 39,48 | 38,41 | 38,98 | +1,48% | 2,78% | 2.244.300 |
| 28/09/2007 | 37,06 | 38,41 | 36,82 | 38,41 | +1,08% | 4,29% | 2.563.500 |
| 27/09/2007 | 37,99 | 38,23 | 37,61 | 38,00 | +0,03% | 1,63% | 1.219.500 |
| 26/09/2007 | 38,80 | 39,20 | 37,88 | 37,99 | -1,35% | 3,40% | 1.155.400 |
| 25/09/2007 | 38,61 | 38,86 | 38,06 | 38,51 | -0,36% | 2,07% | 1.100.800 |
| 24/09/2007 | 38,36 | 38,69 | 37,63 | 38,65 | +1,07% | 2,76% | 902.600 |
| 21/09/2007 | 38,77 | 39,34 | 38,24 | 38,24 | -1,24% | 2,84% | 1.737.500 |
| 20/09/2007 | 38,37 | 39,33 | 38,33 | 38,72 | +0,10% | 2,61% | 1.236.200 |
| 19/09/2007 | 39,36 | 40,10 | 37,33 | 38,68 | -1,75% | 7,04% | 3.042.500 |
| 18/09/2007 | 38,71 | 39,40 | 38,33 | 39,37 | +2,55% | 2,76% | 1.447.000 |
| 17/09/2007 | 40,04 | 40,30 | 38,29 | 38,39 | -4,98% | 5,02% | 1.420.500 |
| 14/09/2007 | 39,75 | 40,59 | 39,45 | 40,40 | +0,75% | 2,87% | 1.122.600 |
| 13/09/2007 | 40,97 | 40,99 | 39,65 | 40,10 | -1,13% | 3,27% | 780.600 |
| 12/09/2007 | 39,96 | 41,00 | 39,79 | 40,56 | +0,42% | 3,03% | 591.000 |
| 11/09/2007 | 40,23 | 40,52 | 39,84 | 40,39 | +1,36% | 1,69% | 718.100 |
| 10/09/2007 | 39,59 | 40,50 | 39,13 | 39,85 | +0,25% | 3,46% | 719.700 |
| 07/09/2007 | 40,29 | 40,60 | 39,50 | 39,75 | -1,85% | 2,73% | 1.198.500 |
| 06/09/2007 | 40,25 | 41,42 | 40,18 | 40,50 | +1,30% | 3,08% | 1.196.500 |
| 05/09/2007 | 39,54 | 40,10 | 39,50 | 39,98 | +1,06% | 1,52% | 1.755.300 |
| 04/09/2007 | 39,27 | 39,95 | 39,26 | 39,56 | +1,54% | 1,76% | 1.997.800 |
| 31/08/2007 | 38,73 | 39,01 | 38,05 | 38,96 | +2,20% | 2,48% | 949.500 |
| 30/08/2007 | 37,39 | 38,81 | 37,20 | 38,12 | +1,22% | 4,31% | 1.485.000 |
| 29/08/2007 | 36,51 | 37,71 | 35,95 | 37,66 | +4,03% | 4,82% | 1.149.600 |
| 28/08/2007 | 36,71 | 36,93 | 36,00 | 36,20 | -1,87% | 2,53% | 952.300 |
| 27/08/2007 | 37,26 | 37,79 | 36,86 | 36,89 | -1,21% | 2,50% | 768.700 |